Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis

Takako Suzuki a, Yukio Nakamura a,b,*, Mikio Kamimura c, Shota Ikegami a, Shigeharu Uchiyama a, Hiroyuki Kato a

* Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan
b Department of Orthopedic Surgery, Showa-Inan General Hospital, Komagane, Japan
c Center of Osteoporosis and Spinal Disorders, Kamimura Orthopaedic Clinic, Matsumoto, Japan

ABSTRACT

Objectives: The aim of this study was to examine the discontinuation and occurrence of fracture during denosumab treatment in Japanese women with primary osteoporosis or rheumatoid arthritis (RA) with osteoporosis.

Methods: This retrospective study included 143 patients with primary osteoporosis and 96 patients with RA and osteoporosis who were treated with denosumab. Treatment discontinuation, fracture occurrence, lumbar spine (L1–L4) bone mineral density (LS-BMD), and bilateral total hip BMD (TH-BMD) were examined before and at 1 and 2 years after treatment commencement.

Results: In the primary osteoporosis group, 32 cases dropped out and no fractures occurred from 0 to 1 year. Eighteen cases were lost to follow-up and no fractures were noted from 1 to 2 years. In the RA with osteoporosis group, 7 cases dropped out and no fracture occurred from 0 to 1 year. Twenty-one cases were lost to follow-up and 2 nonvertebral fractures were noted from 1 to 2 years. In this group, 13 cases dropped out from 1 to 2 years and 16 cases dropped out during the 2-year study period due to economic reasons. LS-BMD and TH-BMD values increased continuously for 2 years of treatment in both primary osteoporosis and RA with osteoporosis groups.

Conclusions: These results suggest that during denosumab therapy, the discontinuation rate is expected to remain low during 2 years of treatment in primary osteoporotic patients. In RA patients with osteoporosis, however, the discontinuation rate may increase due to economic reasons from 1 to 2 years of therapy.

1. Introduction

It is desirable to continue osteoporotic treatment until clinical goals are met since discontinuation and nonadherence to anti-resorptive therapies have been associated with smaller decreases in bone turnover markers, more modest bone mineral density (BMD) gains, and an increased risk of fractures [1]. The continuation of osteoporotic therapies is therefore critical for fracture risk reduction.

Hadji et al. [2] recently described that the 2-year persistence of denosumab was 39.8%, which was 1.5–2 times higher than that for bisphosphonates (BPs), and that risk of discontinuation was significantly lower for denosumab than for BPs. Meanwhile, in rheumatoid arthritis (RA) patients, the risk of both vertebral and nonvertebral fractures accompanying osteoporosis is roughly double as compared with those in subjects without RA [3]. Thus, osteoporotic drugs are considered to be essential for fracture prevention in RA patients with osteoporosis as well, although the compliance of osteoprotic treatment in RA is quite low [3].

Treatment with denosumab causes a strong inhibitory effect on bone resorption markers [4]. Denosumab is also superior with respect to increased BMD and the prevention of both vertebral and hip fractures [5]. The treatment effects of denosumab persist for an extended time, even up to 8 years as reported by Papapoulos et al.
Denosumab is a useful drug in BP-unresponsive primary osteoporosis as well [7]. Despite representing one of the best therapeutic options for osteoporotic patients, there are no reports on the long-term persistence of denosumab in patients with primary osteoporosis or secondary osteoporosis accompanying RA in Japan to date.

The aim of this study was to examine the discontinuation and occurrence of fracture during denosumab treatment in Japanese women with primary osteoporosis or RA with osteoporosis.

2. Materials and methods

In the primary osteoporosis group, 143 primary osteoporotic postmenopausal Japanese women (average age, 76.4 ± 0.9 years; average body mass index [BMI], 20.9 ± 0.3 kg/m²) were retrospectively enrolled between October 2013 and September 2015 as out-patients at our institutions. Among them, 48 patients had taken BPs (alendronate, 17 cases; risedronate, 7 cases; minodronate, 20 cases; ibandronate, 4 cases) and 49 patients had received teriparatide prior to denosumab therapy (Table 1). In the RA with osteoporosis group, 96 patients with RA complicated with secondary osteoporosis (average age, 70.0 ± 0.8 years; average BMI, 20.9 ± 0.4 kg/m²) were retrospectively enrolled. Among them, 63 patients had taken BPs (alendronate, 39 cases; risedronate, 21 cases; minodronate, 3 cases) and 16 patients had received teriparatide prior to denosumab therapy (Table 2).

The diagnosis of RA in this study was conducted in accordance with the 2010 American College of Rheumatology/European League Against Rheumatism classification system [8].

The inclusion criteria for the study were osteoporotic patients with low lumbar spine (L1–4) BMD (LS-BMD) and/or bilateral total hip BMD (TH-BMD) of less than −3.0 standard deviation. The exclusion criteria were the presence of chronic renal failure (estimated glomerular filtration rate <40 mL/min/1.73 m²), bone metabolic disorder, or diabetes mellitus, all of which affected osteoporosis, along with fracture within 1 year prior to the study. The diagnosis of osteoporosis was made in accordance with the revised criteria established by the Japanese Society of Bone and Mineral Research [9].

### Table 1

Patient characteristics prior to denosumab treatment the primary osteoporosis group (n = 143).

| Characteristic                         | Value         |
|----------------------------------------|---------------|
| Age, yr                                | 76.4 ± 0.9    |
| Body mass index, kg/m²                 | 20.9 ± 0.3    |
| Osteoporotic medications before denosumab treatment |                |
| Bisphosphonates                        | 48            |
| Alendronate                            | 17            |
| Risedronate                            | 7             |
| Minodronate                            | 20            |
| Ibandronate                            | 4             |
| BP pretreatment, mo                    | 4.2 ± 0.8     |
| Teriparatide                           | 49            |
| Osteoporotic fractures during the first year | 0            |
| Osteoporotic fractures during the second year | 0            |
| Lumbar spine 1–4 BMD, g/cm²            |               |
| Before                                 | 0.799 ± 0.01  |
| At 1 year (percentage increase)        | 0.832 ± 0.02 (7.6% ± 0.9%***)) |
| At 2 years (percentage increase)       | 0.847 ± 0.02 (10.4% ± 0.8%***)) |
| Total hip BMD, g/cm²                   | 0.629 ± 0.01  |
| Before                                 |               |
| At 1 year (percentage increase)        | 0.640 ± 0.01 (2.8% ± 0.6%***)) |
| At 2 years (percentage increase)       | 0.676 ± 0.01 (5.0% ± 0.7%***)) |

Values are presented as mean ± standard error or number. BP, bisphosphonate; BMD, bone mineral density. ***P < 0.001 compared with before treatment. BMD was measured using a dual-energy X-ray absorptiometer (DXA) fan-beam bone densitometer (Lunar Prodigy; GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) at the L1–4 levels of the posteroanterior spine and bilateral hips. BMD was examined before treatment administration and at 12 and 24 months. Values and percentage changes in BMD were determined for each time point, and comparisons were made between the groups by statistical analysis. The coefficient of variation of the BMD measurements at the lumbar spine and hips were 0.7% and 1.1%, respectively. Routine quality control was ensured using a phantom box. Fracture sites were avoided during the evaluation of BMD. TH-BMD was calculated as the average BMD of the right and left hips. Physicians interpreting the BMD assessments and DXA measurements and the laboratory staff performing the bone marker assays were blinded to the treatment groups.

This study was approved by the Institutional Ethics Committee of Shinshu University School of Medicine and Showa Inan General Hospital. Informed consent was obtained from all patients before interviews by attending physicians. Information was obtained via interview with each patient by the patient’s physician. The methods were carried out in accordance with approved guidelines. The clinical trial registration number is NCT02156960.

3. Results

The number of patients who completed this 2-year investigation was 93 of 143 in the primary osteoporosis group and 68 of 96 in the RA with osteoporosis group. There were no differences between the characteristics of dropout patients.

In the primary osteoporosis group, 32 cases dropped out (22.4%) from 0 to 1 year for unknown reasons (12 cases), economic reasons (3 cases), dental treatment (2 cases), admission to a nursing home (5 cases), hospitalization for another disease (7 cases), transfer to another hospital (2 cases), and death (1 case) according to exit interviews with physicians when applicable. Consequently, 111 patients continued therapy into year 2 (Table 4). No osteoporotic fractures occurred during the first year. LS-BMD values before and at 1 year of treatment were 0.799 ± 0.01 g/cm² and 0.832 ± 0.02 g/cm², respectively, and those of TH-BMD were 0.629 ± 0.01 g/cm² and 0.640 ± 0.01 g/cm², respectively. Compared with baseline values, the percent change of LS-BMD at 12 months was −7.6% ± 0.9% (P < 0.001) and that of TH-BMD was +2.8% ± 0.6% (P < 0.001) (Table 1). These findings indicated high persistence at 12 months (77.6%), no fracture occurrence, and substantially improved BMD values from denosumab treatment. From 1 to 2 years of therapy, 18 cases dropped out (16.2%) due to unknown reasons (6 cases), admission to a nursing home (2 cases), hospitalization for another disease (2 cases), transfer to another hospital (3 cases), and death (5 cases). As a result, 93 patients completed denosumab therapy (Table 4). No fractures occurred during the second year. LS-BMD value at 2 years was 0.847 ± 0.02 g/cm² and that of TH-BMD was 0.676 ± 0.01 g/cm². Compared with baseline values, the percent change of LS-BMD at 24 months was +10.4% ± 0.8% (P < 0.001) and that of TH-BMD was +5.0% ± 0.7% (P < 0.001). From 0 to 2 years, a total of 50
cases dropped out (35.0%) of the study.

In the RA with osteoporosis group, 7 cases dropped out (7.3%) from 0 to 1 year due to economic reasons (3 cases), dental treatment (1 case), transfer to another hospital (2 cases), and death (1 case) according to exit interviews with physicians when applicable. Consequently, 89 patients continued therapy into year 2 (Table 4). No osteoporotic fractures occurred during the first year. LS-BMD values before and at 1 year of treatment were 0.764 ± 0.02 g/cm² and 0.814 ± 0.03 g/cm², respectively, and those of TH-BMD were 0.510 ± 0.02 g/cm² and 0.571 ± 0.02 g/cm², respectively. Compared with before treatment, the percent change of LS-BMD at 12 months was +3.9% ± 0.9% (P < 0.01) and that of TH-BMD was +5.3% ± 1.4% (P < 0.01). These findings indicated high persistence at 12 months (92.7%), no fracture occurrence, and substantially improved BMD values. During 1–2 years of therapy, 21 cases dropped out (23.6%) due to economic reasons (13 cases), hospitalization for another disease (4 cases), and moving (4 cases) (Table 4). As a result, 68 patients completed denosumab therapy. Two nonvertebral fractures occurred between 1 and 2 years at 21 and 23 months. LS-BMD value at 2 years was 0.834 ± 0.04 g/cm² and that of TH-BMD was 0.574 ± 0.03. Compared with baseline values, the percent change of LS-BMD at 24 months

### Table 2

Patient characteristics prior to denosumab treatment in the RA with osteoporosis group (n = 96).

| Characteristic | Value          |
|---------------|----------------|
| Age, yr       | 70.0 ± 0.8     |
| Body mass index, kg/m² | 20.9 ± 0.4 |
| Duration of rheumatoid arthritis, yr | 16.1 ± 1.2 |
| Prednisolone use | 21            |
| Prednisolone dose, mg/d | 5.3 ± 1.0 |
| DAS28CRP      | 3.0 ± 0.4      |
| SDAI          | 11.3 ± 1.4     |
| Biologics     | 41             |
| Tocilizumab   | 4              |
| Adalimumab    | 6              |
| Etanercept    | 11             |
| Infliximab    | 6              |
| Abatacept     | 11             |
| Golimumab     | 3              |

Osteoporotic medications before denosumab treatment

- Bisphosphonates: 63 cases
  - Alendronate: 39 cases
  - Risedronate: 21 cases
  - Minodronate: 3 cases
- BP pretreatment period, mo: 5.0 ± 0.4
- Teriparatide: 16 cases

Osteoporotic fractures during the first year

- 0 cases

Osteoporotic fractures during the second year

- Vertebral: 2 cases
- Nonvertebral: 2 cases

### Table 3

Comparisons of patient characteristics and prevalent fractures prior to denosumab treatment in the osteoporosis and RA with osteoporosis groups.

| Characteristic | Primary osteoporosis | RA with osteoporosis | P-value |
|---------------|----------------------|----------------------|---------|
| Age, yr       | 76.4 ± 0.9           | 70.0 ± 0.8           | <0.01   |
| Body mass index, kg/m² | 20.9 ± 0.3          | 20.9 ± 0.4           | 0.93    |
| Lumbar spine 1–4 BMD, g/cm² | 0.799 ± 0.01     | 0.764 ± 0.02         | 0.17    |
| Total hip BMD, g/cm² | 0.629 ± 0.01      | 0.510 ± 0.02         | <0.01   |
| Prevalent fractures |                   |                      |         |
| Humeral fracture | 1                   | 1                    |         |
| Distal forearm fracture | 1                | 1                    |         |
| Femoral neck or trochanteric fracture | 7               | 5                    |         |
| Patellar fracture | 1                   | 0                    |         |
| Elbow fracture | 0                    | 1                    |         |
| Toe fracture | 0                    | 1                    |         |
| Rib fracture | 0                    | 2                    |         |
| Vertebral fracture | 11                  | 3                    |         |

Values are presented as mean ± standard error or number.

RA, rheumatoid arthritis; SDAI, simplified disease activity index; BP, bisphosphonate; BMD, bone mineral density.

**P < 0.01 compared with before treatment. ***P < 0.001 compared with before treatment.
was $+8.0\% \pm 1.4\% (P < 0.001)$ and that of TH-BMD was $+6.7\% \pm 1.8\% (P < 0.001)$. From 0 to 2 years, a total of 28 cases dropped out (29.2%) of the study. There were no fractures among the dropout cases in either group.

### 4. Discussion

The current study examined the occurrences of discontinuation and fracture during long-term denosumab treatment in Japanese postmenopausal women with primary osteoporosis or RA and osteoporosis. Primary osteoporotic patients exhibited relatively high persistence at 24 months (65.0%) and no occurrence of fracture, while RA patients with osteoporosis displayed high persistence at 24 months (70.8%) and 2 occurrences of fracture. With respect to the reasons for dropout, dental treatment, admission to a nursing home, hospitalization for another disease, transfer to another hospital, moving, and death are largely inevitable, leaving unknown reasons and economic reasons as the only avoidable and true dropout causes.

In the primary osteoporosis group, we observed relatively high persistence at 24 months (65.0%), no fracture occurrence during 0–2 years, and substantially improved BMD values in the second year that was comparable to improvement in the first year. Thus, it is conceivable that during denosumab therapy for primary osteoporosis, avoidable discontinuation may remain consistently low for 0 to 1 and 1–2 years of treatment.

In the RA with osteoporosis group, our findings revealed high persistence at 24 months (70.8%), no dropouts due to unknown reason, and 2 fractures from 1 to 2 years, which was worse than from 0 to 1 year. We witnessed substantially improved BMD values from 1 to 2 years that were similar to those from 0 to 1 year. In RA osteoporotic cases, persistence at 0–1 year was much higher than that in primary osteoporotic cases. The dropout rate was quite high in the latter half of the study due to economic reasons even though denosumab was not very expensive when compared to the costs of biologics. Forty-one RA patients were treated with biologics, as shown in Table 2. Thus, the continuation of denosumab treatment appears to be economically challenging for RA patients, largely due to cost.

Osteoporotic drugs are essential for fracture prevention in RA patients with osteoporosis [3]. Preventing fractures might become an important issue since this study showed that both LS-BMD and TH-BMD were quite low in these patients. Furthermore, Takeuchi et al. [10] reported that denosumab could improve radiographic bone erosion in RA patients. Greater dissemination of the importance of osteoporotic treatment for RA patients using denosumab is therefore needed.

The limitations of this study include a small sample size, short follow-up period, and differences in patient characteristics between the 2 groups. Another limitation was that since prior treatment with other osteoporotic medication was included, the true percentage increase of BMD in treatment-naive patients might be different from that in this study.

### 5. Conclusions

If denosumab treatment can be continued for a year in primary osteoporotic patients, it will be highly possible to maintain therapy for 2 years. In RA patients with osteoporosis, however, it may be challenging to continue denosumab treatment for 2 years due to economic reasons.

### Conflict of interest

No potential conflict of interest relevant to this article was reported.

### References

[1] Bloquin J, Dragomir A, Ste-Marie GC, Fernandes JC, Perreault S. Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. J Clin Endocrinol Metab 2007;92:887–94.

[2] Hadji P, Kyvernitis I, Kann PM, Niedhart C, Hofbauer LC, Schwarz H, et al. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 2016;27:2587–78.

[3] Watt J, Thompson A, Le Riche N, Pope J. There is still a care gap in osteoporosis management for patients with rheumatoid arthritis. Jt Bone Spine 2014;81:347–51.

[4] Nakamura Y, Kaminuma M, Ikegami S, Mukaiyama K, Uchiyama S, Taguchi A, et al. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study. BMC Endocr Disord 2015;15:81.

[5] Leder BZ, Tsai JN, Uhllein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis. (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015;386:1147–55.

[6] Papapoulos S, Lipponen K, Roux C, Lin CJ, Kendlir D, Lewiecki EM, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 2015;26:2773–83.

[7] Kaminuma M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, Taguchi A. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int 2017;28:559–66.

[8] van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum 2011;63:37–42.

[9] Ovino H, Nakamura T, Hosoi T, Ito M, Uemitu K, Endo N, et al. Japanese 2011 Guidelines for prevention and treatment of osteoporosis: executive summary. Arch Osteoporos 2012;7:3–20.

[10] Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with Rheumatoid arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE): a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 2016;75:983–90.